Sotatercept, sold under the brand name Winrevair, is a medication used to treat pulmonary arterial hypertension.[6] It inhibits activin signaling using the extracellular domain of the activin type 2 receptor fused with an immunoglobulin Fc domain (ACTRIIA-Fc) as a recombinant fusion protein.[8] It is administered via subcutaneous injection.[6] The most common side effects include headache, epistaxis (nosebleed), rash, telangiectasia (spider veins), diarrhea, dizziness, and erythema (redness of the skin).[6]
Sotatercept was approved for medical use in the United States in March 2024,[9]